Renal Impairment in Patients With Multiple Myeloma: A Consensus Statement on Behalf of the International Myeloma Working Group
Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Jesús F. San Miguel(Universidad de Salamanca), Nelson Leung(Memorial Sloan Kettering Cancer Center), Patrizia Tosi(Spanish Head & Neck Cancer Cooperative Group), Brian G.M. Durie(Spanish Head & Neck Cancer Cooperative Group), Sundar Jagannath(Mount Sinai Hospital), Heinz Ludwig(Wilhelminen Hospital), Joan Bladé(Spanish Head & Neck Cancer Cooperative Group), Kenneth C. Anderson(Novartis (Switzerland)), Raymond L. Comenzo(Memorial Sloan Kettering Cancer Center), Evangelos Terpos(National and Kapodistrian University of Athens), Paul G. Richardson(Dana-Farber Cancer Institute), Orhan Sezer(Charité - Universitätsmedizin Berlin), Antonio Palumbo(Azienda Ospedaliero Universitaria San Giovanni Battista), S. Vincent Rajkumar(Mayo Clinic), Sergio Giralt(Memorial Sloan Kettering Cancer Center), Michèle Cavo(University of Bologna), Rubén Niesvizky(Cornell University), Jean‐Luc Harousseau, Asher Chanan-Khan(Memorial Sloan Kettering Cancer Center), Bart Barlogie(Spanish Head & Neck Cancer Cooperative Group), Jean-Paul Fermand(Hôpital Saint-Louis), Pieter Sonneveld(Erasmus MC Cancer Institute)
Cited by 409
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k